Acetato de lanreotida para o tratamento de tumores neuroendócrinos gastroenteropancreáticos
Brasil. Ministério da Saúde. Secretaria de Ciência, Tecnologia e Insumos Estratégicos.
Brasília; CONITEC; abr. 2018. graf, ilus, tab.
Não convencional em Português | LILACS, BRISA/RedTESA | ID: biblio-905575
Cost-effectiveness analysis of somatostatin analogues in the treatment of acromegaly in Brazil
Aggressive tumors and difficult choices in acromegaly.
Inhibition of Peripheral Synthesis of Serotonin as a New Target in Neuroendocrine Tumors.
Clinical, quality of life, and economic value of acromegaly disease control.
Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumours in clinical practice: a retrospective cross-sectional analysis.
Advances in small bowel neuroendocrine neoplasia.
The role of primary pharmacological therapy in acromegaly.
SOM230: a new therapeutic modality for Cushing's disease.
Conversion of daily pegvisomant to weekly pegvisomant combined with long-acting somatostatin analogs, in controlled acromegaly patients.
Role of somatostatin analogs in the management of neuroendocrine tumors.